Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04862286 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
A Phase 3 study of Psoriasis, sponsored by AbbVie.
- Active
- Registry status
- Phase 3
- Development phase
- 132
- Enrollment target
- 20
- Study locations
NCT04862286 is a Phase 3 study of Psoriasis that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 132 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT04862286, a Phase 3 study of Psoriasis, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 132 participants
- Enrollment target
- 20
- Study locations
Study Summary
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study evaluates adverse events and change in disease activity with risankizumab in pediatric participants with moderate to severe plaque psoriasis who completed the study M19-977. Risankizumab is an approved drug for treatment of moderate to severe plaque psoriasis in adults and is being studied in the pediatric population (6 to 17 years). A maximum of 132 participants will be enrolled in the study across approximately 50 sites worldwide. Participants will receive subcutaneous injection of risankizumab every 12 weeks for 204 weeks and are followed up for safety for 20 weeks after last dose. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions Studied
Interventions
- DRUG Risankizumab
Study Locations (20)
California
- First OC Dermatology /ID# 226942 - Fountain Valley
- Integrative Skin Science and Research /ID# 226108 - Sacramento
- University of California San Diego - Rady Children's Hospital San Diego /ID# 252348 - San Diego
Florida
- Solutions Through Adv Rch /ID# 226104 - Jacksonville
- Olympian Clinical Research- St. Petersburg /ID# 226106 - St. Petersburg
- Advanced Clinical Research Institute /ID# 248827 - Tampa
Illinois
- University Dermatology and Vein Clinic, LLC /ID# 226100 - Darien
- Arlington Dermatology /ID# 226097 - Rolling Meadows
Ohio
- Univ Hosp Cleveland /ID# 248825 - Cleveland
- Apex Clinical Research Center /ID# 248830 - Mayfield Heights
North Rhine-Westphalia
- Universitaetsklinikum Bonn /ID# 243910 - Bonn
- Universitaetsklinikum Muenster /ID# 243905 - Münster
Alabama
- UAB Department of Dermatology /ID# 252305 - Birmingham
Nevada
- Skin Cancer and Dermatology Institute - Reno /ID# 248828 - Reno
South Carolina
- Medical University of South Carolina /ID# 248831 - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2021-07-24 |
| Est. Completion | 2028-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04862286
The ClinicalTrials.gov registry entry for NCT04862286 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (73% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Risankizumab is the first listed.
NCT04862286 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT04862286 about?
NCT04862286 is a clinical study titled "Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977". Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study evaluates adverse events and change in disease activity with risankizumab in pediatric participants with moderate to severe plaque psoriasis who ...
What is the current status of trial NCT04862286?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 132 participants. The study started on 2021-07-24. Estimated completion is 2028-04.
What conditions does trial NCT04862286 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT04862286?
The interventions under investigation include: Risankizumab (DRUG).
Who is sponsoring clinical trial NCT04862286?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04862286 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
-
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.